Range of qualified clients: CDEC talked over the uncertainty in the quantity of clients with moderately significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some clients that are categorized as acquiring gentle or moderate disease may have a intense bleeding phen